Immunogenicity of a Live Attenuated Chimeric Japanese Encephalitis Vaccine as a Booster Dose After Primary Vaccination With Live Attenuated SA14-14-2 Vaccine: A Phase IV Study in Thai Children

Pediatr Infect Dis J. 2017 Feb;36(2):e45-e47. doi: 10.1097/INF.0000000000001395.

Abstract

This single-group study investigated the immunogenicity and safety of a booster dose of the recently licensed live attenuated chimeric Japanese encephalitis vaccine in 50 healthy children (1-5 years old) who were primed with the live attenuated SA14-14-2 vaccine. A strong anamnestic response was induced 28 days postbooster: geometric mean titer, 9144 (95% confidence interval: 7365-11353); and seroprotection rate, 49 of 49 (100%) children.

Trial registration: ClinicalTrials.gov NCT02526550.

Publication types

  • Clinical Trial, Phase IV
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neutralizing / blood
  • Antibodies, Viral / blood*
  • Child, Preschool
  • Encephalitis Viruses, Japanese / immunology*
  • Encephalitis, Japanese / prevention & control
  • Humans
  • Immunization, Secondary
  • Infant
  • Japanese Encephalitis Vaccines / administration & dosage
  • Japanese Encephalitis Vaccines / adverse effects
  • Japanese Encephalitis Vaccines / immunology*
  • Thailand
  • Vaccines, Attenuated / administration & dosage
  • Vaccines, Attenuated / adverse effects
  • Vaccines, Attenuated / immunology*

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Japanese Encephalitis Vaccines
  • Vaccines, Attenuated

Associated data

  • ClinicalTrials.gov/NCT02526550